ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
6
views
0
references
Top references
cited by
1
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
946
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Lung adenocarcinoma harboring EGFR 19del/C797S/T790M triple mutations responds to brigatinib and anti-EGFR antibody combination therapy
Author(s):
X. WANG
,
L Zhou
,
JC Yin
,
X WU
,
YW Shao
,
BJ Gao
Publication date:
2019
Journal:
J Thorac Oncol
Read this article at
ScienceOpen
PubMed
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Anti-Trafficking Review
Author and article information
Journal
PubMed ID::
30711650
Data availability:
Comments
Comment on this article
Sign in to comment
Similar content
946
Brigatinib outperforms crizotinib as first-line therapy
Authors:
et al., Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status
Authors:
S. Gettinger
,
S. ZHANG
,
J. Hodgson
U.S. FDA Approves Takeda’s ALUNBRIG (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer
Authors:
See all similar
Cited by
1
Durable Clinical Response of Advanced Lung Adenocarcinoma Harboring EGFR-19del/T790M/BRAF V600E Mutations After Treating with Osimertinib and Dabrafenib Plus Trametinib: A Case Report
Authors:
Honggang Ding
,
Zhenjie Zhuang
,
Jingyi Xie
…
See all cited by